1 research outputs found
Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy
Cancer
immunotherapy has made enormous progress in offering safer
and more effective treatments for the disease. Specifically, programmed
death ligand 1 antibody (αPDL1), designed to perform immune
checkpoint blockade (ICB), is now considered a pillar in cancer immunotherapy.
However, due to the complexity and heterogeneity of tumors, as well
as the diversity in patient response, ICB therapy only has a 30% success
rate, at most; moreover, the efficacy of ICB can be evaluated only
two months after start of treatment. Therefore, early identification
of potential responders and nonresponders to therapy, using noninvasive
means, is crucial for improving treatment decisions. Here, we report
a straightforward approach for fast, image-guided prediction of therapeutic
response to ICB. In a colon cancer mouse model, we demonstrate that
the combination of computed tomography imaging and gold nanoparticles
conjugated to αPDL1 allowed prediction of therapeutic response,
as early as 48 h after treatment. This was achieved by noninvasive
measurement of nanoparticle accumulation levels within the tumors.
Moreover, we show that the nanoparticles efficiently prevented tumor
growth with only a fifth of the standard dosage of clinical care.
This technology may be developed into a powerful tool for early and
noninvasive patient stratification as responders or nonresponders